UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

Eli Lilly and Company (NYSE:LLY) Goldman Sachs 43rd Annual Global Healthcare Conference June 14, 2022 1:40 PM ET Company Participants Anne White - SVP and President, Lilly Neuroscience Mark Mintun - SVP, R&D, Neuroscience and President, Avid Radiopharmaceuticals Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, we're good. Thank you very much, everybody, and welcome to this Tuesday session at the Goldman Sachs Healthcare Conference. My name is Chris Shibutani. I'm a member o ...

Eli Lilly and Company (NYSE:LLY) 82nd Scientific Sessions of the American Diabetes Association conference June 7, 2022 11:30 AM ET Company Participants Lauren Zierke - Senior Director of Investor Relations Mike Mason - President of Lilly Diabetes Jeff Emmick - Vice President of Diabetes Product Development Ruth Gimeno - Vice President of Diabetes Research & Clinical Investigation Conference Call Participants Seamus Fernandez - Guggenheim Chris Schott - JPMorgan Steve Scala - Cowen Geoff Meacham - Bank of Am ...

Summary of Eli Lilly and Company (NYSE: LLY) at UBS Global Healthcare Conference Company Overview - **Company**: Eli Lilly and Company - **Event**: UBS Global Healthcare Conference - **Date**: May 24, 2022 - **Key Participant**: Mike Mason, President of Lilly Diabetes Key Points Industry and Product Focus - **Diabetes and Obesity Treatment**: Eli Lilly is focusing on diabetes and obesity treatments, particularly through its products Jardiance and Mounjaro [3][4][83]. Jardiance Performance - **Market Share**: Jardiance has achieved a new treatment share market above 64% and has seen close to 30% year-on-year growth [3][4]. - **Product Expansion**: The product is being positioned not only for Type 2 diabetes but also for cardiovascular issues and chronic kidney disease (CKD) [3]. Mounjaro Launch Strategy - **Approval and Efficacy**: Mounjaro has been approved for Type 2 diabetes, showing significant weight loss of up to 52 pounds in a 72-week study [4][29]. - **Target Market**: The launch strategy focuses on patients who are out of control with their diabetes, rather than switching existing patients from Trulicity [6][7]. - **Pricing Strategy**: Mounjaro is priced approximately 9.9% above Trulicity, with a focus on balancing value and broad access [8][10]. Market Access and Payer Engagement - **Formulary Access**: Discussions with payers are ongoing, and the company is optimistic about gaining broad access at the set price point [14]. - **Patient Support Programs**: Eli Lilly plans to implement support programs, including a $25 co-pay card and month-long samples, to facilitate patient access [17][18]. Competitive Landscape - **Cannibalization Concerns**: There is an acknowledgment of potential cannibalization of Trulicity sales by Mounjaro, but the focus remains on establishing Mounjaro as a long-term solution for Type 2 diabetes [22][24]. - **Market Dynamics**: The company is aware of the competitive landscape, particularly with Novo Nordisk's products, and aims to differentiate Mounjaro based on its unique benefits [41][45]. Future Developments - **Obesity Indication**: Eli Lilly is preparing for a filing for obesity indication in 2024, with ongoing trials (SURMOUNT-2, 3, and 4) expected to provide additional data [31][32]. - **NASH Trials**: The company is conducting Phase II trials for NASH, exploring the potential benefits of tirzepatide in reducing liver fat [70]. Market Trends and Challenges - **SGLT2 Market Growth**: The SGLT2 class is experiencing growth, particularly in heart failure and CKD, with a noted increase in market share [73]. - **Pricing Pressures**: There are ongoing discussions about pricing dynamics in the insulin and GLP-1 markets, with expectations of continued competition and potential pricing pressures [52][54]. Closing Remarks - **Transformative Potential**: Eli Lilly expresses confidence in the transformative potential of Mounjaro and its ability to address significant health needs in diabetes and obesity [83]. This summary encapsulates the key insights from the conference, highlighting Eli Lilly's strategic focus on diabetes and obesity treatments, market positioning, and future growth opportunities.

Eli Lilly and Company (NYSE:LLY) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Kevin Hern - Vice President, Investor Relations Dave Ricks - Chair and CEO Anat Ashkenazi - Chief Financial Officer Dr. Dan Skovronsky - Chief Scientific and Medical Officer Anne White - President, Lilly Neuroscience Ilya Yuffa - President, Lilly International Jake Van Naarden - Chief Executive Officer, Loxo Oncology, Lilly and President, Lilly Oncology Mike Mason - President, Lilly Diabetes Patr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip cod ...